Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk

Stem Cells Translational Medicine

Volumn 1, Issue 10, 2012, Pages 709-718

  Smith, Alyson J ^a,b   Nelson, Natalie G ^b   Oommen, Saji ^a,b   Hartjes, Katherine A ^b   Folmes, Clifford D ^a   Terzic, Andre ^a,b   Nelson, Timothy J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Apoptosis; Pluripotent stem cells; Stem cell transplantation; Stem cells; Tumor cell purging

Indexed keywords

BH3 PROTEIN; KRUPPEL LIKE FACTOR 4; LIPOCORTIN 5; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN; PUMA PROTEIN; SHORT HAIRPIN RNA; TOXIC SUBSTANCE; TRANSCRIPTION FACTOR SOX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DAUGHTER CELL; DNA DAMAGE; EMBRYONIC STEM CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; GENOMIC INSTABILITY; HISTOLOGY; HYPERSENSITIVITY; MOUSE; NONHUMAN; ONCOGENE C MYC; PLURIPOTENT STEM CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK; SOMATIC CELL; SPECTRAL KARYOTYPING; STEM CELL TRANSPLANTATION; TERATOMA; TOXICITY; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84876510977     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0066     Document Type: Article

References (37)

1. Segers VFM, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008;451:937-942.
2. Nelson TJ, Martinez-Fernandez A, Yamada S et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 2009;120:408-416.
3. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344:710-719.
4. Goldring CEP, Duffy PA, Benvenisty N et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell 2011;8:618-628.
5. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011;11:268-277.
6. Bjorklund LM, Sanchez-Pernaute R, Chung S et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99:2344-2349.
7. Tang C, Lee AS, Volkmer J-P et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratomaforming cells. Nat Biotechnol 2011;29:829-834.
8. Cheng F, Ke Q, Chen F et al. Protecting against wayward human induced pluripotent stem cells with a suicide gene. Biomaterials 2012;33:3195-3204.
9. Knoepfler PS. Deconstructing stem cell tumorigenicity: A roadmap to safe regenerative medicine. STEM CELLS 2009; 27:1050-1056.
10. Bieberich E, Silva J, Wang G et al. Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants. J Cell Biol 2004;167:723-734.
11. Francis R, Richardson C. Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements. Genes Dev 2007; 21:1064-1074.
12. Cervantes RB, Stringer JR, Shao C et al. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc Natl Acad Sci USA 2002; 99:3586-3590.
13. Donoho G, Jasin M, Berg P. Analysis of gene targeting and intrachromosomal homologous recombination stimulated by genomic double-strand breaks in mouse embryonic stem cells. Mol Cell Biol 1998;18:4070-4078.
14. Saretzki G, Armstrong L, Leake A et al. Stress defense in murine embryonic stem cells is Superior to that of various differentiated murine cells. STEM CELLS 2004;22:962-971.
15. de Waard H, Sonneveld E, de Wit J et al. Cell-type-specific consequences of nucleotide excision repair deficiencies: Embryonic stem cells versus fibroblasts. DNA Repair 2008; 7: 1659-1669.
16. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 2010;24:1680-1694.
17. Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460:53-59.
18. Raya A, Rodriguez-Piza I, Navarro S et al. A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. Nat Protoc 2010;5:647-660.
19. Müller LUW, Milsom MD, Harris CE et al. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 2012; 119:5449-5457.
20. Aladjem MI, Spike BT, Rodewald LW et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 1998;8:145-155.
21. Corbet SW, Clarke AR, Gledhill S et al. p53dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells. Oncogene 1999;18:1537-1544.
22. Sabapathy K, Klemm M, Jaenisch R et al. Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 1997;16:6217-6229.
23. Heyer BS, MacAuley A, Behrendtsen O et al. Hypersensitivity to DNA damage leads to increased apoptosis during early mouse development. Genes Dev 2000;14:2072-2084.
24. Roos WP, Christmann M, Fraser ST et al. Mouse embryonic stem cells are hypersensitive to apoptosis triggered by the DNA damage O6-methylguanine due to high E2F1 regulated mismatch repair. Cell Death Differ 2007;14: 1422-1432.
25. Ardehali R, Inlay MA, Ali SR et al. Overexpression of BCL2 enhances survival of human embryonic stem cells during stress and obviates the requirement for serum factors. Proc Natl Acad Sci USA 2011;108:3282-3287.
26. Hong Y, Stambrook PJ. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci USA 2004;101:14443-14448.
27. Momcilovic O, Knobloch L, Fornsaglio J et al. DNA damage responses in human induced pluripotent stem cells and embryonic stem cells. PLoS One 2010;5:e13410.
28. Marión RM. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460: 1149-1153.
29. Grandela C, Pera MF, Wolvetang EJ. p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Stem Cell Res 2007;1: 116-128.
30. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008;27:S71-S83.
31. Madden DT, Davila-Kruger D, Melov S et al. Human embryonic stem cells express elevated levels of multiple pro-apoptotic BCL-2 family members. PLoS One 2011;6:e28530.
32. Lake BB, Fink J, Klemetsaune L et al. Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma. STEM CELLS 2012;30:888-897.
33. Draper JS, Smith K, Gokhale P et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 2004;22:53-54.
34. Baker DEC, Harrison NJ, Maltby E et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 2007;25:207-215.
35. Lefort N, Feyeux M, Bas C et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat Biotechnol 2008; 26: 1364-1366.
36. Bueno C, Catalina P, Melen GJ et al. Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis 2009;30:1628-1637.
37. Edick MJ, Gajjar A, Mahmoud HH et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003; 21:1340-1346.